These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24592552)

  • 1. Is really megacolon a contraindication to infliximab in Crohn's disease?
    Sinagra E; Orlando A; Renna S; Criscuoli V; La Seta F; Olivo M; Ciofalo M; Cottone M
    Acta Gastroenterol Belg; 2013 Dec; 76(4):442-4. PubMed ID: 24592552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab in Crohn's disease-associated toxic megacolon.
    van Geenen EJ; Sachar DB
    J Clin Gastroenterol; 2012 Apr; 46(4):321-3. PubMed ID: 21857531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab treatment for toxic megacolon in severe colonic Crohn's disease.
    Irabien M; Arreba P; Ortiz de Zárate J; Hernández-Aretxabaleta N; de la Maza-Ortiz S; Ispizua-Madariaga N; Muñoz-Villafranca C
    Rev Esp Enferm Dig; 2021 Mar; 113(3):189-192. PubMed ID: 33244975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant Crohn's colitis: when only an antibody will do.
    Ng SC; Kamm MA
    Inflamm Bowel Dis; 2007 Aug; 13(8):971-4. PubMed ID: 17427240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
    Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
    Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Infliximab treatment of severe bleeding complicating Crohn's disease].
    Julián Gómez L; Atienza R; Barrio J; Gil P; Gómez de la Cuesta S; Pinto P; Alcaide N; Caro Patón A
    Rev Esp Enferm Dig; 2010 Jan; 102(1):57-8. PubMed ID: 20187687
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in pathogenesis, incidence and outcome of perforation in inflammatory bowel disease.
    Greenstein AJ; Aufses AH
    Surg Gynecol Obstet; 1985 Jan; 160(1):63-9. PubMed ID: 3871126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Toxic megacolon as a complication of ulcerative colitis and Crohn's disease of the colon. When and how to operate. Experience in 10 cases].
    Berti Riboli E; Bertoglio C; Reboa G; Terrizzi A
    Minerva Dietol Gastroenterol; 1980; 26(3):153-6. PubMed ID: 7254577
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.
    Harper JW; Sinanan MN; Zisman TL
    Inflamm Bowel Dis; 2013 Sep; 19(10):2118-24. PubMed ID: 23863401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crohn's disease of the colon. III. Toxic dilatation of the colon in Crohn's colitis.
    Greenstein AJ; Kark AE; Dreiling DA
    Am J Gastroenterol; 1975 Feb; 63(2):117-28. PubMed ID: 165716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic megacolon complicating ulcerative colitis and Crohn's disease.
    Cunsolo A; Bragaglia RB; Arena N; Mastromatteo MG; Vecchi R; Gozzetti G
    Int Surg; 1985; 70(4):339-43. PubMed ID: 3833841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab-induced psoriasis during therapy for Crohn's disease.
    Steinwurz F; Denadai R; Saad-Hossne R; Queiroz ML; Teixeira FV; Romiti R
    J Crohns Colitis; 2012 Jun; 6(5):610-6. PubMed ID: 22398095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to Infliximab in children with luminal Crohn's disease.
    Grover Z; Biron R; Carman N; Lewindon P
    J Crohns Colitis; 2014 Aug; 8(8):739-46. PubMed ID: 24445015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue therapy with tacrolimus in a patient with toxic megacolon.
    Pascu M; Müller AR; Wiedenmann B; Dignass AU
    Int J Colorectal Dis; 2003 May; 18(3):271-5. PubMed ID: 12785330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.